<html>

<head>
<meta http-equiv=Content-Type content="text/html; charset=windows-1252">
<meta name=Generator content="Microsoft Word 15 (filtered)">
<title>HB 934 (Edition 1)</title>
<style>
<!--
 /* Font Definitions */
 @font-face
	{font-family:"Cambria Math";
	panose-1:2 4 5 3 5 4 6 3 2 4;}
@font-face
	{font-family:"Times New \(W1\)";}
@font-face
	{font-family:IDAutomationHC39M;
	panose-1:2 0 5 9 0 0 0 2 0 4;}
 /* Style Definitions */
 p.MsoNormal, li.MsoNormal, div.MsoNormal
	{margin:0in;
	margin-bottom:.0001pt;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;}
p.MsoToc1, li.MsoToc1, div.MsoToc1
	{margin-top:6.0pt;
	margin-right:0in;
	margin-bottom:6.0pt;
	margin-left:0in;
	page-break-after:avoid;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;
	text-transform:uppercase;
	font-weight:bold;}
p.MsoToc2, li.MsoToc2, div.MsoToc2
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:12.25pt;
	margin-bottom:.0001pt;
	page-break-after:avoid;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;
	text-transform:uppercase;}
p.MsoToc3, li.MsoToc3, div.MsoToc3
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:23.75pt;
	margin-bottom:.0001pt;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;}
p.MsoHeader, li.MsoHeader, div.MsoHeader
	{mso-style-link:"Header Char";
	margin:0in;
	margin-bottom:.0001pt;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;}
p.MsoFooter, li.MsoFooter, div.MsoFooter
	{mso-style-link:"Footer Char";
	margin:0in;
	margin-bottom:.0001pt;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;}
span.MsoLineNumber
	{font-family:"Times New Roman",serif;}
p.LMSBase, li.LMSBase, div.LMSBase
	{mso-style-name:LMSBase;
	margin:0in;
	margin-bottom:.0001pt;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;}
p.aArticle, li.aArticle, div.aArticle
	{mso-style-name:aArticle;
	mso-style-link:"aArticle Char";
	margin:0in;
	margin-bottom:.0001pt;
	text-align:center;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;}
p.aArticleTitle, li.aArticleTitle, div.aArticleTitle
	{mso-style-name:aArticleTitle;
	mso-style-link:"aArticleTitle Char";
	margin:0in;
	margin-bottom:.0001pt;
	text-align:center;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;}
p.aBase, li.aBase, div.aBase
	{mso-style-name:aBase;
	margin:0in;
	margin-bottom:.0001pt;
	text-align:justify;
	text-justify:inter-ideograph;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;}
p.aBillSection, li.aBillSection, div.aBillSection
	{mso-style-name:aBillSection;
	margin:0in;
	margin-bottom:.0001pt;
	text-align:justify;
	text-justify:inter-ideograph;
	text-indent:.75in;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;}
p.aBlock1, li.aBlock1, div.aBlock1
	{mso-style-name:aBlock1;
	mso-style-link:"aBlock1 Char";
	margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:1.25in;
	margin-bottom:.0001pt;
	text-align:justify;
	text-justify:inter-ideograph;
	text-indent:-.5in;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;}
p.aBlock2, li.aBlock2, div.aBlock2
	{mso-style-name:aBlock2;
	mso-style-link:"aBlock2 Char";
	margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:1.75in;
	margin-bottom:.0001pt;
	text-align:justify;
	text-justify:inter-ideograph;
	text-indent:-.5in;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;}
p.aBlock3, li.aBlock3, div.aBlock3
	{mso-style-name:aBlock3;
	margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:2.25in;
	margin-bottom:.0001pt;
	text-align:justify;
	text-justify:inter-ideograph;
	text-indent:-.5in;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;}
p.aBlock4, li.aBlock4, div.aBlock4
	{mso-style-name:aBlock4;
	margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:2.75in;
	margin-bottom:.0001pt;
	text-align:justify;
	text-justify:inter-ideograph;
	text-indent:-.5in;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;}
p.aBlock5, li.aBlock5, div.aBlock5
	{mso-style-name:aBlock5;
	margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:3.25in;
	margin-bottom:.0001pt;
	text-align:justify;
	text-justify:inter-ideograph;
	text-indent:-.5in;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;}
p.aChapter, li.aChapter, div.aChapter
	{mso-style-name:aChapter;
	margin:0in;
	margin-bottom:.0001pt;
	text-align:center;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;
	font-weight:bold;}
p.aHeading, li.aHeading, div.aHeading
	{mso-style-name:aHeading;
	margin:0in;
	margin-bottom:.0001pt;
	text-align:justify;
	text-justify:inter-ideograph;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;
	text-transform:uppercase;
	font-weight:bold;}
p.aLongTitle, li.aLongTitle, div.aLongTitle
	{mso-style-name:aLongTitle;
	margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:.25in;
	margin-bottom:.0001pt;
	text-align:justify;
	text-justify:inter-ideograph;
	text-indent:-.25in;
	font-size:12.0pt;
	font-family:"Times New \(W1\)";
	text-transform:uppercase;}
p.aMargin1, li.aMargin1, div.aMargin1
	{mso-style-name:aMargin1;
	mso-style-link:"aMargin1 Char";
	margin:0in;
	margin-bottom:.0001pt;
	text-align:justify;
	text-justify:inter-ideograph;
	text-indent:.25in;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;}
p.aMargin2, li.aMargin2, div.aMargin2
	{mso-style-name:aMargin2;
	margin:0in;
	margin-bottom:.0001pt;
	text-align:justify;
	text-justify:inter-ideograph;
	text-indent:.75in;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;}
p.aPart, li.aPart, div.aPart
	{mso-style-name:aPart;
	margin:0in;
	margin-bottom:.0001pt;
	text-align:center;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;}
p.aSection, li.aSection, div.aSection
	{mso-style-name:aSection;
	mso-style-link:"aSection Char";
	margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:.75in;
	margin-bottom:.0001pt;
	text-align:justify;
	text-justify:inter-ideograph;
	text-indent:-.75in;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;
	font-weight:bold;}
p.aSP, li.aSP, div.aSP
	{mso-style-name:aSP;
	margin:0in;
	margin-bottom:.0001pt;
	text-align:justify;
	text-justify:inter-ideograph;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;
	color:blue;
	font-weight:bold;}
p.aSPComment, li.aSPComment, div.aSPComment
	{mso-style-name:aSPComment;
	margin:0in;
	margin-bottom:.0001pt;
	font-size:12.0pt;
	font-family:"Times New \(W1\)";
	color:red;
	display:none;
	font-weight:bold;}
p.aSPFunds1, li.aSPFunds1, div.aSPFunds1
	{mso-style-name:aSPFunds1;
	margin:0in;
	margin-bottom:.0001pt;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;}
p.aSPFunds2, li.aSPFunds2, div.aSPFunds2
	{mso-style-name:aSPFunds2;
	margin:0in;
	margin-bottom:.0001pt;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;}
p.aSPFundsHeading1, li.aSPFundsHeading1, div.aSPFundsHeading1
	{mso-style-name:aSPFundsHeading1;
	margin:0in;
	margin-bottom:.0001pt;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;
	font-weight:bold;}
p.aSPFundsHeading2, li.aSPFundsHeading2, div.aSPFundsHeading2
	{mso-style-name:aSPFundsHeading2;
	margin:0in;
	margin-bottom:.0001pt;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;
	font-weight:bold;}
p.aSPHeading, li.aSPHeading, div.aSPHeading
	{mso-style-name:aSPHeading;
	margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:1.0in;
	margin-bottom:.0001pt;
	text-align:justify;
	text-justify:inter-ideograph;
	text-indent:-1.0in;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;
	text-transform:uppercase;
	font-weight:bold;}
p.nonumber, li.nonumber, div.nonumber
	{mso-style-name:nonumber;
	margin:0in;
	margin-bottom:.0001pt;
	text-align:justify;
	text-justify:inter-ideograph;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;}
p.aSPHeadingLine, li.aSPHeadingLine, div.aSPHeadingLine
	{mso-style-name:aSPHeadingLine;
	margin:0in;
	margin-bottom:.0001pt;
	text-align:justify;
	text-justify:inter-ideograph;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;
	font-weight:bold;}
p.ASPlist, li.ASPlist, div.ASPlist
	{mso-style-name:ASPlist;
	margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:2.5in;
	margin-bottom:.0001pt;
	text-indent:-1.75in;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;}
p.aSPRequestedBY, li.aSPRequestedBY, div.aSPRequestedBY
	{mso-style-name:aSPRequestedBY;
	margin:0in;
	margin-bottom:.0001pt;
	font-size:12.0pt;
	font-family:"Times New \(W1\)";}
p.aSPTitle, li.aSPTitle, div.aSPTitle
	{mso-style-name:aSPTitle;
	margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:.25in;
	margin-bottom:.0001pt;
	text-align:justify;
	text-justify:inter-ideograph;
	text-indent:-.25in;
	font-size:12.0pt;
	font-family:"Times New \(W1\)";
	text-transform:uppercase;
	font-weight:bold;}
p.aSubChapter, li.aSubChapter, div.aSubChapter
	{mso-style-name:aSubChapter;
	margin:0in;
	margin-bottom:.0001pt;
	text-align:center;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;
	text-transform:uppercase;
	font-weight:bold;}
p.aSubPart, li.aSubPart, div.aSubPart
	{mso-style-name:aSubPart;
	margin:0in;
	margin-bottom:.0001pt;
	text-align:center;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;}
p.aTitle, li.aTitle, div.aTitle
	{mso-style-name:aTitle;
	margin:0in;
	margin-bottom:.0001pt;
	text-align:center;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;}
span.cHistoryNote
	{mso-style-name:cHistoryNote;}
span.FooterChar
	{mso-style-name:"Footer Char";
	mso-style-link:Footer;
	font-family:"Times New Roman",serif;}
span.HeaderChar
	{mso-style-name:"Header Char";
	mso-style-link:Header;
	font-family:"Times New Roman",serif;}
p.TOCPageHeader, li.TOCPageHeader, div.TOCPageHeader
	{mso-style-name:TOCPageHeader;
	margin:0in;
	margin-bottom:.0001pt;
	text-align:center;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;
	text-transform:uppercase;
	font-weight:bold;}
p.aSPSubTitle, li.aSPSubTitle, div.aSPSubTitle
	{mso-style-name:aSPSubTitle;
	margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:.25in;
	margin-bottom:.0001pt;
	text-align:justify;
	text-justify:inter-ideograph;
	text-indent:-.25in;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;
	text-transform:uppercase;
	font-weight:bold;}
p.aSPHeadingMiscellaneous, li.aSPHeadingMiscellaneous, div.aSPHeadingMiscellaneous
	{mso-style-name:aSPHeadingMiscellaneous;
	margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:1.0in;
	margin-bottom:.0001pt;
	text-align:justify;
	text-justify:inter-ideograph;
	text-indent:-1.0in;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;
	text-transform:uppercase;
	font-weight:bold;}
p.aDistrict, li.aDistrict, div.aDistrict
	{mso-style-name:aDistrict;
	margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:.2in;
	margin-bottom:.0001pt;
	text-align:justify;
	text-justify:inter-ideograph;
	text-indent:-.2in;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;}
span.aArticleChar
	{mso-style-name:"aArticle Char";
	mso-style-link:aArticle;
	font-family:"Times New Roman",serif;}
span.aArticleTitleChar
	{mso-style-name:"aArticleTitle Char";
	mso-style-link:aArticleTitle;
	font-family:"Times New Roman",serif;}
span.aMargin1Char
	{mso-style-name:"aMargin1 Char";
	mso-style-link:aMargin1;
	font-family:"Times New Roman",serif;}
span.aSectionChar
	{mso-style-name:"aSection Char";
	mso-style-link:aSection;
	font-family:"Times New Roman",serif;
	font-weight:bold;}
span.aBlock1Char
	{mso-style-name:"aBlock1 Char";
	mso-style-link:aBlock1;
	font-family:"Times New Roman",serif;}
span.aBlock2Char
	{mso-style-name:"aBlock2 Char";
	mso-style-link:aBlock2;
	font-family:"Times New Roman",serif;}
.MsoChpDefault
	{font-family:"Calibri",sans-serif;}
.MsoPapDefault
	{margin-bottom:10.0pt;
	line-height:115%;}
 /* Page Definitions */
 @page WordSection1
	{size:8.5in 11.0in;
	margin:.6in .9in .5in 1.2in;}
div.WordSection1
	{page:WordSection1;}
-->
</style>

</head>

<body lang=EN-US>

<div class=WordSection1>

<p class=nonumber align=center style='margin-top:24.0pt;text-align:center'><b>GENERAL
ASSEMBLY OF NORTH CAROLINA</b></p>

<p class=nonumber align=center style='margin-top:3.0pt;margin-right:0in;
margin-bottom:6.0pt;margin-left:0in;text-align:center'><b>SESSION 2019</b></p>

<p class=nonumber align=left style='text-align:left'><b>H                                                                                                                                                    1</b></p>

<p class=nonumber align=center style='text-align:center'><b>HOUSE BILL 934</b></p>

<p class=nonumber align=center style='text-align:center'><b>&nbsp;</b></p>

<p class=nonumber align=center style='text-align:center'><b>&nbsp;</b></p>

<table class=MsoNormalTable border=1 cellspacing=0 cellpadding=0 width=0
 style='width:6.55in;margin-left:-5.75pt;border-collapse:collapse;border:none'>
 <tr>
  <td width=527 colspan=2 valign=top style='width:395.25pt;border:none;
  border-bottom:solid windowtext 1.0pt;padding:0in .05in 0in 5.4pt'>
  <p class=nonumber align=left style='margin-bottom:6.0pt;text-align:left'>Short
  Title:      Right to Try Adult Stem Cell Treatments.</p>
  </td>
  <td width=102 valign=top style='width:76.35pt;border:none;border-bottom:solid windowtext 1.0pt;
  padding:0in .05in 0in 5.4pt'>
  <p class=nonumber align=right style='margin-bottom:6.0pt;text-align:right'>(Public)</p>
  </td>
 </tr>
 <tr>
  <td width=96 valign=top style='width:71.85pt;border:none;border-bottom:solid windowtext 1.0pt;
  padding:0in .05in 0in 5.4pt'>
  <p class=nonumber align=left style='margin-top:3.0pt;margin-right:0in;
  margin-bottom:3.0pt;margin-left:0in;text-align:left'>Sponsors:</p>
  </td>
  <td width=533 colspan=2 valign=top style='width:399.75pt;border:none;
  border-bottom:solid windowtext 1.0pt;padding:0in .05in 0in 5.4pt'>
  <p class=nonumber align=left style='margin-top:3.0pt;margin-right:0in;
  margin-bottom:3.0pt;margin-left:0in;text-align:left'>Representatives
  Blackwell, Lambeth, Murphy, and Reives (Primary Sponsors).</p>
  <p class=nonumber align=center style='margin-top:3.0pt;margin-right:0in;
  margin-bottom:3.0pt;margin-left:0in;text-align:center'><i><span
  style='font-size:10.0pt'>For a complete list of sponsors, refer to the North
  Carolina General Assembly web site.</span></i></p>
  </td>
 </tr>
 <tr>
  <td width=96 valign=top style='width:71.85pt;border:none;border-bottom:solid windowtext 1.0pt;
  padding:0in .05in 0in 5.4pt'>
  <p class=nonumber align=left style='margin-top:3.0pt;margin-right:0in;
  margin-bottom:3.0pt;margin-left:0in;text-align:left'>Referred to:</p>
  </td>
  <td width=533 colspan=2 valign=top style='width:399.75pt;border:none;
  border-bottom:solid windowtext 1.0pt;padding:0in .05in 0in 5.4pt'>
  <p class=nonumber style='margin-top:3.0pt;margin-right:0in;margin-bottom:
  3.0pt;margin-left:0in'>Health, if favorable, Rules, Calendar, and Operations
  of the House</p>
  </td>
 </tr>
 <tr height=0>
  <td width=96 style='border:none'></td>
  <td width=431 style='border:none'></td>
  <td width=102 style='border:none'></td>
 </tr>
</table>

<p class=nonumber align=center style='margin-top:6.0pt;margin-right:0in;
margin-bottom:12.0pt;margin-left:0in;text-align:center'>April 22, 2019</p>

<p class=aBase align=center style='text-align:center'><span style='color:black'>A
BILL TO BE ENTITLED</span></p>

<p class=aLongTitle><span style='font-family:"Times New Roman",serif;
color:black'>AN ACT EXPANDING THE RIGHT TO TRY ACT TO PROVIDE ACCESS TO
INVESTIGATIONAL ADULT STEM CELL TREATMENTS FOR PATIENTS DIAGNOSED WITH a
TERMINAL OR CHRONIC ILLNESS.</span></p>

<p class=aBase><span style='color:black'>The General Assembly of North Carolina
enacts:</span></p>

<p class=aBillSection><b><span style='color:black'>SECTION 1.</span></b><span
style='color:black'>  Article 23A of Chapter 90 of the General Statutes reads
as rewritten:</span></p>

<p class=aArticle><span style='color:black'>&quot;Article 23A.</span></p>

<p class=aArticleTitle><span style='color:black'>&quot;Right to Try Act.</span></p>

<p class=aPart><span style='color:black'>&quot;<u>Part 1. Experimental
Treatments.</u></span></p>

<p class=aSection><span style='color:black;font-weight:normal'>&quot;</span><span
style='color:black'>§ 90&#8209;325.  Short title; purpose.</span></p>

<p class=aMargin1><span style='color:black'>(a)        This Article shall be
known and may be cited as the Right to Try Act.</span></p>

<p class=aMargin1><span style='color:black'>(b)        The purpose of <u>Part 1
of </u>this Article is to authorize access to and use of experimental
treatments for patients with a terminal illness; to establish conditions for
use of experimental treatment; to prohibit sanctions of health care providers
solely for recommending or providing experimental treatment; to clarify duties
of a health insurer with regard to experimental treatment authorized under this
<s>Article; </s><u>Part; </u>to prohibit certain actions by State officials,
employees, and agents; and to restrict certain causes of action arising from
experimental treatment.</span></p>

<p class=aSection><span style='color:black;font-weight:normal'>&quot;</span><span
style='color:black'>§ 90&#8209;325.1.  Definitions.</span></p>

<p class=aMargin1><span style='color:black'>The following definitions apply in
this <s>Article, </s><u>Part, </u>unless the context requires otherwise:</span></p>

<p class=aBlock1><span style='color:black'>(1)        Eligible patient. – An
individual who meets all of the following criteria:</span></p>

<p class=aBlock2><span style='color:black'>a.         Has a terminal illness,
attested to by a treating physician.</span></p>

<p class=aBlock2><span style='color:black'>b.         Has, in consultation with
a treating physician, considered all other treatment options currently approved
by the United States Food and Drug Administration.</span></p>

<p class=aBlock2><span style='color:black'>c.         Has received a
recommendation from the treating physician for use of an investigational drug,
biological product, or device for treatment of the terminal illness.</span></p>

<p class=aBlock2><span style='color:black'>d.         Has given informed
consent in writing to use of the investigational drug, biological product, or
device for treatment of the terminal illness or, if the individual is a minor
or is otherwise incapable of providing informed consent, the parent or legal
guardian has given informed consent in writing to use of the investigational
drug, biological product, or device.</span></p>

<p class=aBlock2><span style='color:black'>e.         Has documentation from
the treating physician that the individual meets all of the criteria for this
definition. This documentation shall include an attestation from the treating
physician that the treating physician was consulted in the creation of the
written, informed consent required under this <s>Article.</s><u>Part.</u></span></p>

<p class=aBlock1><span style='color:black'>…</span></p>

<p class=aSection><span style='color:black;font-weight:normal'>&quot;</span><span
style='color:black'>§ 90&#8209;325.2.  Authorized access to and use of
investigational drugs, biological products, and devices.</span></p>

<p class=aMargin1><span style='color:black'>(a)        A manufacturer of an
investigational drug, biological product, or device may make available to an
eligible patient, and an eligible patient may request, the manufacturer's
investigational drug, biological product, or device. However, nothing in this <s>Article
</s><u>Part </u>shall be construed to require a manufacturer of an
investigational drug, biological product, or device to make such
investigational drug, biological product, or device available to an eligible
patient.</span></p>

<p class=aMargin1><span style='color:black'>(b)        A manufacturer of an
investigational drug, biological product, or device may provide the
investigational drug, biological product, or device to an eligible patient
without receiving compensation or may require the eligible patient to pay the
costs of, or the costs associated with, the manufacture of the investigational
drug, biological product, or device.</span></p>

<p class=aSection><span style='color:black;font-weight:normal'>…</span></p>

<p class=aSection><span style='color:black;font-weight:normal'>&quot;</span><span
style='color:black'>§ 90&#8209;325.6.  No private right of action against
manufacturers of investigational drugs, biological products, or devices.</span></p>

<p class=aMargin1><span style='color:black'>No private right of action may be
brought against a manufacturer of an investigational drug, biological product,
or device, or against any other person or entity involved in the care of an
eligible patient using an investigational drug, biological product, or device,
for any harm caused to the eligible patient resulting from use of the
investigational drug, biological product, or device as long as the manufacturer
or other person or entity has made a good&#8209;faith effort to comply with the
provisions of this <s>Article </s><u>Part </u>and has exercised reasonable care
in actions undertaken pursuant to this <s>Article.</s><u>Part.</u></span></p>

<p class=aSection><span style='color:black;font-weight:normal'>&quot;</span><span
style='color:black'>§ 90&#8209;325.7.  Insurance coverage of clinical trials.</span></p>

<p class=aMargin1><span style='color:black'>Nothing in this <s>Article </s><u>Part
</u>shall be construed to affect a health benefit plan's obligation to provide
coverage for an insured's participation in a clinical trial pursuant to
G.S.&nbsp;58&#8209;3&#8209;255.</span></p>

<p class=aSection><span style='color:black;font-weight:normal'>&quot;</span><u><span
style='color:black'>§ 90&#8209;325.8.</span></u><span style='color:black'> 
Reserved.</span></p>

<p class=aSection><span style='color:black;font-weight:normal'>&quot;</span><u><span
style='color:black'>§ 90&#8209;325.9.</span></u><span style='color:black'> 
Reserved.</span></p>

<p class=aPart><span style='color:black'>&quot;<u>Part 2. Investigational Adult
Stem Cell Treatments.</u></span></p>

<p class=aSection><span style='color:black;font-weight:normal'>&quot;</span><u><span
style='color:black'>§ 90&#8209;325.10.  Purpose.</span></u></p>

<p class=aMargin1><u><span style='color:black'>The purpose of Part 2 of this
Article is to authorize access to and use of certain investigational adult stem
cell treatments for patients with certain severe chronic diseases or terminal
illnesses; to regulate the possession, use, and transfer of adult stem cells;
and to create a criminal offense for the purchase and sale of adult stem cells
for certain investigational treatments.</span></u></p>

<p class=aSection><span style='color:black;font-weight:normal'>&quot;</span><u><span
style='color:black'>§ 90&#8209;325.11.  Definitions.</span></u></p>

<p class=aMargin1><u><span style='color:black'>The following definitions apply
in this Part unless the context requires otherwise:</span></u></p>

<p class=aBlock1><u><span style='color:black'>(1)</span></u><span
style='color:black'>        <u>Adult stem cell. – An undifferentiated cell that
is (i) found in postnatal differentiated tissue and (ii) able to renew itself
and differentiate to yield all or nearly all of the specialized cell types of
the tissue from which the cell originated.</u></span></p>

<p class=aBlock1><u><span style='color:black'>(2)</span></u><span
style='color:black'>        <u>Clinical trial. – A research study in which one
or more human subjects are prospectively assigned to one or more interventions
using adult stem cells administered under United States Food and Drug
Administration protocols for Investigational New Drugs or Investigational
Device Exemptions.</u></span></p>

<p class=aBlock1><u><span style='color:black'>(3)</span></u><span
style='color:black'>        <u>Investigational adult stem cell treatment. –
Adult stem cell treatment that meets all of the following criteria:</u></span></p>

<p class=aBlock2><u><span style='color:black'>a.</span></u><span
style='color:black'>         <u>Is under investigation in a clinical trial and
being administered to human participants in that trial.</u></span></p>

<p class=aBlock2><u><span style='color:black'>b.</span></u><span
style='color:black'>         <u>Has not yet been approved for general use by
the United States Food and Drug Administration.</u></span></p>

<p class=aBlock1><u><span style='color:black'>(4)</span></u><span
style='color:black'>        <u>Eligible patient. – An individual who meets all
of the following criteria:</u></span></p>

<p class=aBlock2><u><span style='color:black'>a.</span></u><span
style='color:black'>         <u>Has a severe chronic disease or terminal illness,
attested to by a treating physician.</u></span></p>

<p class=aBlock2><u><span style='color:black'>b.</span></u><span
style='color:black'>         <u>Has, in consultation with a treating physician,
considered all other treatment options currently approved by the United States
Food and Drug Administration.</u></span></p>

<p class=aBlock2><u><span style='color:black'>c.</span></u><span
style='color:black'>         <u>Has received a recommendation from the treating
physician for use of an investigational adult stem cell treatment for the
severe chronic disease or terminal illness.</u></span></p>

<p class=aBlock2><u><span style='color:black'>d.</span></u><span
style='color:black'>         <u>Has given informed consent in writing to use of
the investigational adult stem cell treatment or, if the individual is a minor
or is otherwise incapable of providing informed consent, the parent or legal
guardian has given informed consent in writing to use of the investigational adult
stem cell treatment.</u></span></p>

<p class=aBlock2><u><span style='color:black'>e.</span></u><span
style='color:black'>         <u>Has documentation from the treating physician
that the individual meets all of the criteria for this definition. This
documentation shall include an attestation from the treating physician that the
treating physician was consulted in the creation of the written, informed
consent required under this Part.</u></span></p>

<p class=aBlock1><u><span style='color:black'>(5)</span></u><span
style='color:black'>        <u>Severe chronic disease. – A condition, injury,
or illness that meets all of the following criteria:</u></span></p>

<p class=aBlock2><u><span style='color:black'>a.</span></u><span
style='color:black'>         <u>May be treated.</u></span></p>

<p class=aBlock2><u><span style='color:black'>b.</span></u><span
style='color:black'>         <u>Is never cured or eliminated.</u></span></p>

<p class=aBlock2><u><span style='color:black'>c.</span></u><span
style='color:black'>         <u>Entails significant functional impairment or
severe pain.</u></span></p>

<p class=aBlock1><u><span style='color:black'>(6)</span></u><span
style='color:black'>        <u>Terminal illness. – As defined in G.S.&nbsp;90&#8209;325.1(3).</u></span></p>

<p class=aBlock1><u><span style='color:black'>(7)</span></u><span
style='color:black'>        <u>Written, informed consent. – A written document
that is signed by an eligible patient; or if the patient is a minor, by a
parent or legal guardian; or if the patient is incapacitated, by a designated
health care agent pursuant to a health care power of attorney, that at a
minimum includes all of the following:</u></span></p>

<p class=aBlock2><u><span style='color:black'>a.</span></u><span
style='color:black'>         <u>An explanation of the currently approved
products and treatments for the eligible patient's severe chronic disease or
terminal illness.</u></span></p>

<p class=aBlock2><u><span style='color:black'>b.</span></u><span
style='color:black'>         <u>An attestation that the eligible patient
concurs with the treating physician in believing that all currently approved
treatments are unlikely to alleviate the significant impairment or severe pain
associated with a severe chronic disease or unlikely to prolong the life of an eligible
patient with a terminal illness.</u></span></p>

<p class=aBlock2><u><span style='color:black'>c.</span></u><span
style='color:black'>         <u>Clear identification of the specific
investigational adult stem cell treatment proposed for treatment of the
eligible patient's severe chronic disease or terminal illness.</u></span></p>

<p class=aBlock2><u><span style='color:black'>d.</span></u><span
style='color:black'>         <u>A description of the potentially best and worst
outcomes resulting from use of the investigational adult stem cell treatment to
treat the eligible patient's severe chronic disease or terminal illness, along
with a realistic description of the most likely outcome. The description shall
be based on the treating physician's knowledge of the proposed treatment in
conjunction with an awareness of the eligible patient's severe chronic disease
or terminal illness and shall include a statement acknowledging that new,
unanticipated, different, or worse symptoms might result from, and that death
could be hastened by, the proposed treatment.</u></span></p>

<p class=aBlock2><u><span style='color:black'>e.</span></u><span
style='color:black'>         <u>A statement that eligibility for hospice care
may be withdrawn if the eligible patient begins treatment of the terminal
illness with an investigational adult stem cell treatment and that hospice care
may be reinstated if such treatment ends and the eligible patient meets hospice
eligibility requirements.</u></span></p>

<p class=aBlock2><u><span style='color:black'>f.</span></u><span
style='color:black'>          <u>A statement that the eligible patient's health
benefit plan or third&#8209;party administrator and provider are not obligated
to pay for any care or treatments consequent to the use of the investigational adult
stem cell treatment, unless specifically required to do so by law or contract.</u></span></p>

<p class=aBlock2><u><span style='color:black'>g.</span></u><span
style='color:black'>         <u>A statement that the eligible patient understands
that he or she is liable for all expenses consequent to the investigational adult
stem cell treatment and that this liability extends to the eligible patient's
estate, unless a contract between the patient and provider of the
investigational stem cell treatment states otherwise.</u></span></p>

<p class=aBlock2><u><span style='color:black'>h.</span></u><span
style='color:black'>         <u>A statement that the eligible patient or, for
an eligible patient who is a minor or lacks capacity to provide informed
consent, that the parent or legal guardian consents to the use of the
investigational adult stem cell treatment for treatment of the severe chronic
disease or terminal condition.</u></span></p>

<p class=aSection><span style='color:black;font-weight:normal'>&quot;</span><u><span
style='color:black'>§ 90&#8209;325.12.  Authorized treatments.</span></u></p>

<p class=aMargin1><u><span style='color:black'>(a)</span></u><span
style='color:black'>        <u>An eligible patient is authorized to access and
use an investigational adult stem cell treatment under this Part, if the investigational
adult stem cell treatment meets all of the following requirements:</u></span></p>

<p class=aBlock1><u><span style='color:black'>(1)</span></u><span
style='color:black'>        <u>Is administered directly by a physician
certified by an institutional review board that meets the requirements of G.S.&nbsp;90&#8209;325.13.</u></span></p>

<p class=aBlock1><u><span style='color:black'>(2)</span></u><span
style='color:black'>        <u>Is overseen by an institutional review board that
meets the requirements of G.S.&nbsp;90&#8209;325.13.</u></span></p>

<p class=aBlock1><u><span style='color:black'>(3)</span></u><span
style='color:black'>        <u>Is provided at one of the following:</u></span></p>

<p class=aBlock2><u><span style='color:black'>a.</span></u><span
style='color:black'>         <u>A hospital licensed under Chapter 131E of the
General Statutes.</u></span></p>

<p class=aBlock2><u><span style='color:black'>b.</span></u><span
style='color:black'>         <u>An ambulatory surgical center licensed under
Chapter 131E of the General Statutes.</u></span></p>

<p class=aBlock2><u><span style='color:black'>c.</span></u><span
style='color:black'>         <u>An accredited medical school located in this
State.</u></span></p>

<p class=aMargin1><u><span style='color:black'>(b)</span></u><span
style='color:black'>        <u>A physician administering an investigational
adult stem cell treatment under this Part shall comply with all applicable rules
of the North Carolina Medical Board.</u></span></p>

<p class=aMargin1><u><span style='color:black'>(c)</span></u><span
style='color:black'>        <u>This Part does not affect or authorize a person
to violate any applicable laws regulating the possession, use, or transfer of human
organs, fetal tissue, fetal stem cells, adult stem cells, or embryonic stem
cells or their derivatives.</u></span></p>

<p class=aSection><span style='color:black;font-weight:normal'>&quot;</span><u><span
style='color:black'>§ 90&#8209;325.13.  Institutional review boards; annual report;
rules.</span></u></p>

<p class=aMargin1><u><span style='color:black'>(a)</span></u><span
style='color:black'>        <u>An institutional review board that oversees investigational
adult stem cell treatments administered under this Part is required to be
affiliated with an accredited medical school located in this State, or a hospital
licensed under Chapter 131E of the General Statutes with at least 150 beds. An
institutional review board that meets the requirements of this subsection may
certify physicians to provide investigational adult stem cell treatment under
this Part.</u></span></p>

<p class=aMargin1><u><span style='color:black'>(b)</span></u><span
style='color:black'>        <u>An institutional review board overseeing an
investigational adult stem cell treatment under this Part shall keep a record
on each person to whom a physician administers the treatment and document in
the record the provision of each treatment and the effects of the treatment on
the person throughout the period the treatment is administered to the person.</u></span></p>

<p class=aMargin1><u><span style='color:black'>(c)</span></u><span
style='color:black'>        <u>Each institutional review board overseeing an
investigational adult stem cell treatment under this Part shall submit an
annual report to the North Carolina Medical Board on the review board's
findings based on records kept under subsection (b) of this section. The report
shall not include any patient&#8209;identifying information and must be made
available to the public in both written and electronic form.</u></span></p>

<p class=aMargin1><u><span style='color:black'>(d)</span></u><span
style='color:black'>       <u>The North Carolina Medical Board may adopt rules
concerning the role and function of institutional review boards under this
Part.</u></span></p>

<p class=aSection><span style='color:black;font-weight:normal'>&quot;</span><u><span
style='color:black'>§ 90&#8209;325.14.  Prohibited purchase and sale of adult
stem cells for certain investigational treatments.</span></u></p>

<p class=aMargin1><u><span style='color:black'>(a)</span></u><span
style='color:black'>        <u>Except as allowed under subsection (c) of this
section, it is unlawful to knowingly offer to buy, offer to sell, acquire,
receive, sell, or otherwise transfer any adult stem cells for valuable
consideration for use in an investigational adult stem cell treatment.</u></span></p>

<p class=aMargin1><u><span style='color:black'>(b)</span></u><span
style='color:black'>        <u>Subsection (b) of this section does not prohibit
the following forms of valuable consideration for investigational adult stem
cell treatment:</u></span></p>

<p class=aBlock1><u><span style='color:black'>(1)</span></u><span
style='color:black'>        <u>A fee paid to a health care provider for
services rendered in the usual course of medical practice or a fee paid for
hospital or other clinical services.</u></span></p>

<p class=aBlock1><u><span style='color:black'>(2)</span></u><span
style='color:black'>        <u>Reimbursement of legal or medical expenses
incurred for the benefit of the ultimate receiver of the investigational adult
stem cell treatment.</u></span></p>

<p class=aBlock1><u><span style='color:black'>(3)</span></u><span
style='color:black'>        <u>Reimbursement of expenses for travel, housing,
and lost wages incurred by the donor of adult stem cells in connection with the
donation of the adult stem cells.</u></span></p>

<p class=aMargin1><u><span style='color:black'>(c)</span></u><span
style='color:black'>        <u>It is an exception to the application of this
section that the actor engaged in conduct authorized under G.S.&nbsp;130A&#8209;412.31.</u></span></p>

<p class=aMargin1><u><span style='color:black'>(d)</span></u><span
style='color:black'>       <u>A violation of this section is a Class A
misdemeanor.</u></span></p>

<p class=aSection><span style='color:black;font-weight:normal'>&quot;</span><u><span
style='color:black'>§ 90&#8209;325.15.  Sanctions against physicians prohibited.</span></u></p>

<p class=aMargin1><u><span style='color:black'>(a)</span></u><span
style='color:black'>        <u>A licensing board shall not revoke, fail to
renew, suspend, or take any other disciplinary action against a physician
licensed under this Chapter, based solely on the physician's recommendation
that an eligible patient have access to an investigational adult stem cell
treatment, or the physician's administration of an investigational adult stem
cell treatment to the eligible patient, provided that the recommendation made
or the care provided is consistent with the applicable standard of care and the
requirements of this Part.</u></span></p>

<p class=aMargin1><u><span style='color:black'>(b)</span></u><span
style='color:black'>        <u>An entity responsible for Medicare certification
shall not take action against a physician's Medicare certification based solely
on the physician's recommendation that a patient have access to an
investigational adult stem cell treatment, or the physician's administration of
an investigational adult stem cell treatment to the eligible patient, provided
that the recommendation made or the care provided meets the applicable standard
of care and the requirements of this Part.</u></span></p>

<p class=aSection><span style='color:black;font-weight:normal'>&quot;</span><u><span
style='color:black'>§ 90&#8209;325.16.  Prohibited conduct by government
officials.</span></u></p>

<p class=aMargin1><u><span style='color:black'>No official, employee, or agent
of this State or any of its political subdivisions shall interfere with or
attempt to interfere with an eligible patient's access to an investigational
adult stem cell treatment authorized under this Part. Counseling, advice, or a
recommendation consistent with medical standards of care from a licensed health
care provider does not constitute a violation of this section.</span></u></p>

<p class=aSection><span style='color:black;font-weight:normal'>&quot;</span><u><span
style='color:black'>§ 90&#8209;325.17.  Insurance of clinical trials.</span></u></p>

<p class=aMargin1><u><span style='color:black'>Nothing in this Part shall be
construed to affect a health benefit plan's obligation to provide coverage for
an insured's participation in a clinical trial pursuant to G.S.&nbsp;58&#8209;3&#8209;255.</span></u><span
style='color:black'>&quot;</span></p>

<p class=aBillSection><b><span style='color:black'>SECTION 3.</span></b><span
style='color:black'>  This act becomes effective December 1, 2019, and applies
to acts committed on or after that date.</span></p>

</div>

</body>

</html>
